Global Hypothermic Machine Perfusion Market Size, Share, and COVID-19 Impact Analysis, By Organ Type (Heart, Lung, Kidney, Liver, Pancreas, and Composite Tissue (VCA)), By End User (Transplant Centers, Hospitals, and Academic & Research Institutes), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035
Industry: Healthcare
Global Hypothermic Machine Perfusion Market Insights Forecasts to 2035
- The Global Hypothermic Machine Perfusion Market Size Was Estimated at USD 3185.0 Million in 2024
- The Market Size is Expected to Grow at a CAGR of around 7.05% from 2025 to 2035
- The Worldwide Hypothermic Machine Perfusion Market Size is Expected to Reach USD 6739.5 Million by 2035
- Asia Pacific is expected to grow the fastest during the forecast period.
Get more details on this report -
According to a research report published by Spherical Insights and Consulting, the global Hypothermic Machine Perfusion market size was worth around USD 3185.0 million in 2024 and is predicted to grow to around USD 6739.5 million by 2035 with a compound annual growth rate (CAGR) of 7.05% from 2025 and 2035. The market for hypothermic machine perfusion has a number of opportunities to grow due to increasing improvements in healthcare accessibility, along with favorable government initiatives.
Market Overview
The Global Hypothermic Machine Perfusion Market Size industry focuses on providing technology and devices for preserving donor organs using a cold, oxygenated solution. Hypothermic machine perfusion is an alternative to static cold storage for preserving organs for transplantation, utilising a machine to pump a cold solution through the organ. It is considered as National standard preservation method for deceased donor kidneys. Further, in liver transplantation, hypothermic oxygenated machine perfusion has a lower risk of nonanastomotic biliary structures in livers obtained from donors after circulatory death than conventional static cold storage.
Innovation and market expansion are anticipated as a result of major players' growing research on hypothermic oxygenated machine perfusion. For instance, a case report on ‘Hypothermic Oxygenated Machine Perfusion (HOPE) During Total Vascular Exclusion with Veno-Venous Bypass for Giant Hepatic Hemangioma Resection’ was published on WILEY Online Library.
Report Coverage
This research report categorizes the Hypothermic Machine Perfusion market size based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Hypothermic Machine Perfusion market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Hypothermic Machine Perfusion market.
Driving Factors
The increasing number of organ transplants is primarily propelling the hypothermic machine perfusion market. For instance, it was estimated that more than 144,000 organs were transplanted worldwide in 2021, and under 8200 heart transplants were performed worldwide in 2020. Further, the support of funding and healthcare expenditure, which affect the progress of organ transplantation in terms of quantity and quality, is driving the market for hypothermic machine perfusion. Hypothermic machine perfusion is a superior preservation method compared to traditional static cold storage and appears to be associated with improved short-term outcomes in liver transplantation
Restraining Factors
The hypothermic machine perfusion market is restricted by the increased cost of organ transplantation, ethical concerns, and complications associated with cell-based research. Further, the scarcity of specialized perfusionists and 24/7 transplant-team staffing is challenging the market growth.
Market Segmentation
The hypothermic machine perfusion market share is classified into organ type and end user.
- The kidney segment dominated the market with a significant share of 41.5% in 2024 and is projected to grow at a substantial CAGR during the forecast period.
Based on the organ type, the hypothermic machine perfusion market is divided into heart, lung, kidney, liver, pancreas, and composite tissue (VCA). Among these, the kidney segment dominated the market with a significant share of 41.5% in 2024 and is projected to grow at a substantial CAGR during the forecast period. Kidney transplantation refers to the treatment of choice for patients with end-stage renal disease (ESRD), as it has better outcomes compared to dialysis. An expanding kidney preservation service is contributing to driving the market demand. For instance, in October 2022, Organ Recovery Systems’ LifePort kidney transporter awarded an exclusive contract for kidney transplant preservation services in Belgium.
- The transplant centers segment accounted for the largest revenue share of around 55.1% in 2024 and is anticipated to grow at a significant CAGR during the forecast period.
Based on the end user, the hypothermic machine perfusion market is divided into transplant centers, hospitals, and academic & research institutes. Among these, the transplant centers segment accounted for the largest revenue share of around 55.1% in 2024 and is anticipated to grow at a significant CAGR during the forecast period. For instance, in October 2025, the Transplant Center at Mayo Clinic in Florida performed its 10,000th transplant, which represents reflection of the lives transformed through the gift of organ donation. The presence of specialized trained staff and donor coordination mandates in the transplant centres is responsible for driving the segmental market.
Get more details on this report -
Regional Segment Analysis of the Hypothermic Machine Perfusion Market
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Rest of APAC)
- South America (Brazil and the Rest of South America)
- The Middle East and Africa (UAE, South Africa, Rest of MEA)
North America is anticipated to hold the largest share of the hypothermic machine perfusion market over the predicted timeframe.
North America is anticipated to hold the largest share of over 39.5% in the hypothermic machine perfusion market over the predicted timeframe. The market ecosystem in North America is strong, due to an increasing adoption of cutting-edge organ preservation solutions, with the integration of sensors and AI-driven analytics for monitoring precise organ viability. For instance, in October 2024, Paragonix Technologies received 510(k) clearance from the US Food and Drug Administration (FDA) for its portable donor kidney preservation system, KidneyVault. The market for hypothermic machine perfusion has been driven by the region's supportive regulatory frameworks, along with the presence of robust healthcare infrastructure and increased transplantation rates. The U.S. is the dominating country in the North America hypothermic machine perfusion market with the largest share of approximately 39.1%, driven by the growing number of organ transplants, along with an increasing number of approvals of products utilized for kidney preservation and transplantation.
Asia Pacific is expected to grow at a rapid CAGR of about 6.8% in the hypothermic machine perfusion market during the forecast period. The Asia Pacific area has a thriving market for hypothermic machine perfusion due to its increasing awareness about organ donation, along with the increasing government initiatives for supporting organ transplantation with favourable policies. For instance, in August 2023, Paragonix Technologies announced FDA granted clearance for its next-generation BAROguard donor lung preservation system, which includes the existence of advanced hypothermic preservation technology with automated continuous and active airway pressure control. Japan is leading the Asia Pacific hypothermic machine perfusion market, owing to the integration of AI-driven predictive analytics and machine learning into organ preservation practices in the healthcare sector.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the hypothermic machine perfusion market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Key Companies
- Organ Recovery Systems
- XVIVO
- IGL
- Bridge to Life Ltd
- Vascular Perfusion Solutions, Inc.
- Paragonix Technologies
- TransMedics
- Getinge AB
- Medtronic
- LivaNova PLC
- Terumo Corporation
- Others
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Recent Development
- In November 2025, Organ Recovery Systems (ORS), a global leading provider of organ perfusion devices and services, announced that the New England Journal of Medicine (NEJM) published detailed, 10-year follow-up data from a 2009 Mowers et al. landmark clinical study.
- In September 2025, the first-ever multicenter study of Hypothermic Oxygenated Perfusion (HOPE) in pediatric liver transplantation using any machine perfusion devices was presented at the 13th Congress of the International Pediatric Transplant Association (IPTA) in Berlin, Germany.
- In January 2025, Paragonix Technologies, a pioneer in organ transplant technologies and organ procurement services, announced the completion of world’s first in human cases utilizing its FDA-cleared KidneyVault Portable Renal Perfusion System, marking a new chapter in kidney transplant preservation.
- In December 2024, Bridge to Life Ltd., a leader in organ preservation solutions and perfusion technology, acquired the VitaSmart Hypothermic Oxygenated Machine Perfusion System from Medica S.p.A.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the hypothermic machine perfusion market based on the below-mentioned segments:
Global Hypothermic Machine Perfusion Market, By Organ Type
- Heart
- Lung
- Kidney
- Liver
- Pancreas
- Composite Tissue (VCA)
Global Hypothermic Machine Perfusion Market, By End User
- Transplant Centers
- Hospitals
- Academic & Research Institutes
Global Hypothermic Machine Perfusion Market, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
Need help to buy this report?